Impact of educational intervention on the awareness of undergraduate medical students towards teratogenicity: an observational study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20183500Keywords:
Drugs, Pregnancy, Teratogenicity, Teratogenic factors, Undergraduate studentsAbstract
Background: The term teratogenicity is defined as any morphological, behavioral or biochemical effect induced during embryonic life or fetal life detected at birth or later. the factors that lead to teratogenicity include both non-genetic and genetic factors. The objective of the present study was to assess the impact of educational interventions on the awareness of undergraduate medical students towards teratogenicity
Methods: The present study was a questionnaire-based comparative observational study carried out at Department of Pharmacology and Therapeutics, Government Medical College, Jammu (J&K) for a period of three months from 1st November 2017 to 31st January 2018. The questionnaire was designed and validated by conducting pilot study on a sample of ten students. The questionnaire comprised of two main parts. The first part comprised of questions pertaining to the demographic profile of the students and second part consisted of questions assessing the students’ knowledge and awareness towards teratogenicity. The scoring of the assessment of the performance of the students regarding knowledge of various aspects of teratogenicity was done before and after the educational intervention and was compared using paired t-test.
Results: A total of 134 second year MBBS undergraduate students participated in the study. Mean age of students was 19.32±0.82 years. In the present study it was found that before the educational intervention about 98.5% of the students and after the intervention all the students were aware of the term teratogenicity. About 69.4% of students knew about all the causes that lead to teratogenicity but after the intervention about 76.1% of the students knew about it. Also, the percentage of students who knew about the name of two teratogenic drugs and two teratogenic defects associated with drugs were only 31.3% and 22.3% respectively. After the educational intervention it increased to 61.9% and 52.2% respectively.
Conclusions: In the present study, it was found that after the educational intervention, there was a significant improvement in the mean knowledge score of the students. This reflects the need of early exposure of students to this important issue of teratogenicity.
Metrics
References
Bisht M, Dhasmana DC. Teratagenecity and Maternogenicity. Myths and Facts. RJPBCS. 2014;5(1):452-69.
Sharma R. Birth defects in India: Hidden truth, need for urgent attention. Indian J Hum Genet. 2013;19(2):125-9.
Fraser FC. Foreward: What is teratology?. In: Hales B, Scialli A, Tassinari MS, editors. Teratology primer: Teratology society. 2010. p. viii-ix. Available at http://connection.teratology.org/p/cm/ld/ fid=6
Gregg NM. Congenital cataract following German measles in the mother. 1941. Aust N Z J Ophthalmol. 1991;19:267-76.
Webster WS. Teratogen update: Congenital rubella. Teratology. 1998;58:13-23.
McBride WB. Thalidomide and congenital abnormalities. Lancet. 1961;21358
Lenz W, Knapp K. Thalidomide embryopathy. Arch Environ Health. 1962; 5:100-105.
Rang HP, Dale MM, Ritter JM, Fowler RJ. The Harmful effects of drugs. In: Rang and Dale’s pharmacology, 6th edition. Edinburgh, UK: Churchill Livingstone 2007; Chapter 53:pp.757-758.
Dutta DC. Pharmacotherapeutics in Obstetrics. In: Konar H (editor), Textbook of obstetrics including perinatology and contraception, 6th edition. New Central Book Agency (P) LTD, 2006;511.
World Health Organization. Fact sheet: Congenital anomalies, 2016. Available at http://www.who.int/mediacentre/factsheets/fs370/en/. Accessed on 11th December, 2017.
Tripathi KD. Adverse drug effects. Section I: General Pharmacological Principles. In : Essentials of Medical Pharmacology, 7th edition. Jaypee Brothers Medical Publishers (P) Ltd. 2013;89-90.
National Health Portal. Congenital anomalies (birth defects), 2016. Available at https://www.nhp.gov.in/disease/gynaecology-andobstetrics/congenital-anomalies-birth-defects. Accessed on 11th December 2017.
Kar A. Birth Defects in India: Magnitude, Public Health Impact and Prevention. JKIMSU. 2014;3(2):716.
Banhidy F, Lowry RB, Czeizel AE. Risk and benefit of drug use during pregnancy. Int J Med Sci. 2005;2:100-6.
Yawn B, Knudtson M. Treating asthma and comorbid allergic rhinitis in pregnancy. J Am Board Fam Med. 2007;20:289-98.
Yankowitz J, Niebyl JR. Drug Therapy in Pregnancy. 3rd ed. USA: Lippincott Williams & Wilkins; 2001.
Centers for Disease Control and Prevention. Understanding the Causes of Major Birth Defects: Steps to Prevention, 2015. Available at https://www.cdc.gov/cdcgrandrounds/pdf/archives/20 15/january2015.pdf. Accessed on 18th December 2017.
Kumari P, Krishnaiah V, Kumaraswamy G, Tamboli TJ. Impact of educational session on knowledge and attitude towards teratogenicity among undergraduate medical students: a comparative study. Int J Basic Clin Pharmacol. 2017;6:2642-5.
Banu G, Khan AAK. A questionnaire based survey on knowledge, attitude and practices of medical practitioners regarding the prescribing of medications during pregnancy. Int J Reprod Contracept Obstet Gynecol. 2016;5:984-8.
Downloads
Published
How to Cite
Issue
Section
